Request a quote

Please leave a message

×

Invalid Captcha
Thank you for your message.

Stilla® Crystal Digital PCR™ technology for absolute ­quantification of nucleic acids is based on ­cutting-edge microfluidic technology that ­integrates the digital PCR process in a single consumable, ­reducing the hands-on time and interaction, so users can simply insert the sample and walk away.

The sample is partitioned using a network of microchannels into a large array of individual droplets, also called a droplet crystal. Owing to the next-generation Crystal Digital PCR™ technology, the droplets partitioned are identical in size- ­yielding results you can trust. PCR then ­amplifies the ­fluorescent target in the droplets which can be read for ­absolute quantification the nucleic acids.

With a combination of powerful imaging, the flexibility to use up to 3 detection channels, and a proprietary software for analysis, Crystal Digital PCR™ is designed to offer an unmatched level of confidence in the digital PCR ­measurement.

Key Features

Easy-to-use solution

  • On-chip integrated workflow
  • Minimal hands-on time

Flexible digital PCR

  • Up to 3-color target multiplexing
  • Two chip formats: from 12 to 48 samples/run

Fast time-to-results

  • Prepare (15 min), Amplify (2 hrs), Read (10-20 min), Analyze (5 min)

Featured Products

The entire naica® system workflow

Crystal Digital PCR™ is Stilla’s next-generation technology for absolute quantification of nucleic acids. Using cutting-edge microfluidic innovations, this technology integrates the digital PCR process in a single consumable.

Stilla TechnologiesAt Stilla Technologies, we continuously innovate and evolve technologically toward better human health outcomes. Our global team with multidisciplinary expertise shares a passion to develop new products for advanced genetic testing and analysis. Our expertise spans from microfluidics and chemistry to molecular biology and computer science. Our product, the naica® System, has been adopted by researchers & clinicians around the world to develop a wide range of genetic tests and molecular biology assays – including, but not limited to, liquid biopsy tests for cancer diagnostics, infectious diseases, prenatal testing, and GMO detection.
[]